Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7697156 | 0.82 | ALDH1A1 (0.45) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL15442983 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL634058 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL15443027 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL15443392 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL702109 | 0.79 | ADRB2 (0.45) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL2306124 | 0.79 | ALDH1A1 (0.42) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL8845360 | 0.78 | ALDH1A1 (0.42) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL6350238 | 0.78 | ALDH1A1 (0.44) | ALDH1A1ADRB2ADRB1ADRB3KMT2A | |
| SCHEMBL9806822 | 0.77 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324273-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | ALDH1A1 636/4885ADRB2 537/4885ADRB1 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.